Isethionate salt of a selective CDK4 inhibitor
First Claim
Patent Images
1. An isethionate salt of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one comprising a mono-isethionate salt of Form A, characterized by one or more of the following:
- a powder X-ray diffraction pattern having peaks at 2θ
values of about 8.7, 13.5, and 17.6, or a Raman spectrum having peaks at Raman Shift values of about 1600 cm−
1, 1290 cm−
1, 675 cm−
1, 470 cm−
1, 450 cm−
1, and 425 cm−
1, or a DSC thermogram having a sharp endotherm at about 273°
C.
1 Assignment
0 Petitions
Accused Products
Abstract
Disclosed are polymorphs of the isethionate salt of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one, which is a selective cyclin-dependent kinase 4 (CDK4) inhibitor useful for treating inflammation and cell proliferative diseases such as cancer and restenosis.
-
Citations
4 Claims
-
1. An isethionate salt of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one comprising a mono-isethionate salt of Form A, characterized by one or more of the following:
- a powder X-ray diffraction pattern having peaks at 2θ
values of about 8.7, 13.5, and 17.6, or a Raman spectrum having peaks at Raman Shift values of about 1600 cm−
1, 1290 cm−
1, 675 cm−
1, 470 cm−
1, 450 cm−
1, and 425 cm−
1, or a DSC thermogram having a sharp endotherm at about 273°
C. - View Dependent Claims (4)
- a powder X-ray diffraction pattern having peaks at 2θ
-
2. An isethionate salt of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one comprising a mono-isethionate salt of Form B, characterized by one or more of the following:
- a powder X-ray diffraction pattern having peaks at 2θ
values of about 5.1, 11.8, 12.1, 12.8, 13.1, and 14.7, a Raman spectrum having peaks at Raman Shift values of about 1600 cm−
1, 1290 cm−
1, 470 cm−
1, 450 cm−
1, and 425 cm−
1, but no substantial peak at 675 cm−
1, or a DSC thermogram having a sharp endotherm at about 271°
C.
- a powder X-ray diffraction pattern having peaks at 2θ
-
3. An isethionate salt of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one comprising a mono-isethionate salt of Form D, characterized by one or more of the following:
- a powder X-ray diffraction pattern having peaks at 2θ
values of about 8.4, 8.9, and 21.9, a Raman spectrum having a peak at a Raman Shift value of about 463 cm−
1, or a DSC thermogram having a sharp endotherm at about 277°
C.
- a powder X-ray diffraction pattern having peaks at 2θ
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeWarner-Lambert Company LLC (Pfizer Inc.)
-
Original AssigneeWarner-Lambert Company LLC (Pfizer Inc.)
-
InventorsBlackburn, Anthony Clyde, Erdman, David Thomas, Toogood, Peter Laurence, Beylin, Vladimir Genukh
-
Primary Examiner(s)Wilson; James O
-
Assistant Examiner(s)Jaisle; Cecilia M
-
Application NumberUS11/861,958Publication NumberTime in Patent Office1,196 DaysField of Search514/252.16, 544/279US Class Current514/252.16CPC Class CodesA61P 13/12 of the kidneysA61P 15/00 Drugs for genital or sexual...A61P 17/06 AntipsoriaticsA61P 19/02 for joint disorders, e.g. a...A61P 25/00 Drugs for disorders of the ...A61P 29/00 Non-central analgesic, anti...A61P 3/10 for hyperglycaemia, e.g. an...A61P 31/00 Antiinfectives, i.e. antibi...A61P 31/10 AntimycoticsA61P 31/12 AntiviralsA61P 35/00 Antineoplastic agentsA61P 37/00 Drugs for immunological or ...A61P 37/06 Immunosuppressants, e.g. dr...A61P 43/00 Drugs for specific purposes...A61P 9/00 Drugs for disorders of the ...A61P 9/10 for treating ischaemic or a...C07D 471/04 Ortho-condensed systems
